SR-aGvHD
Steroid-Refractory acute Graft Versus Host Disease

-
HSCT is a treatment in which HSCs of donors are administered to the recipient veins to treat intractable blood diseases.
-
Transplanted HSCs are attached to recipient’s bone marrow and differentiate to platelets, red blood cells, and white blood cells.
-
The acute systemic inflammatory disease in which the transplanted immune cells attack the patient's body is called aGvHD.
-
About 40,000 patients undergo HSCT around the world (2021), of which about 25% patients developed deceased by SR-aGvHD that because conventional treatments including steroids with immunosuppressant are not effective.

-
As a result of non-clinical testing using IntenCell®, the survival rate increased by more than 30%P compared to naïve MSC treatments.
-
Currently, phase 1 clinical trials are being approved by the Ministry of Food and Drug Safety (South Korea) and ongoing clinical trials.
-
If clinical trials are conducted, overall survivor rate of IntenCell®-treated patients were predicted at least 85% compared to existing naïve MSC treatments.